List view / Grid view
11 July 2014 | By Sanofi
Sanofi Pasteur, the vaccines division of Sanofi announced the publication in The Lancet of the detailed results of its first landmark phase III dengue vaccine efficacy study conducted in five countries in Asia...
11 July 2014 | By Bristol-Myers Squibb
...an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma...
10 July 2014 | By kdm communications
Cresset announces the appointment of CloudScientific as distributor of their computational chemistry software in China...
10 July 2014 | By Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health...
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
9 July 2014 | By Fraunhofer
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
9 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg...
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
9 July 2014 | By
Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer. 1,2 It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World.1 The current standard of care is intensive chemotherapy, but many older patients cannot tolerate this therapeutic approach; their…
8 July 2014 | By kdm communications
Tecan has introduced an innovative new consumable device offering increased throughput and capacity for Freedom EVO® workstations...
8 July 2014 | By Novartis
Novartis released new global guidelines for Investigator Initiated Trials...
8 July 2014 | By Sanofi
Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for Toujeo®...
7 July 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza® (daclatasvir)...
7 July 2014 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary...
